ALTRIA GROUP, INC.
NYSE: MO·Richmond, Virginia·CIK 0000764180
- Price
- $78.90
- Base IV
- $76.67
Valuation snapshot
At $78.90, the price is close to our base case of $76.67.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $76.67
- 97% of the price · range $45.34–$104.80
- Price vs base case
- 3% above
- $78.90 against $76.67
- Base case · our researched forecast, 2026-10-31See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $45.34 to bull $104.80. Values per share.
Price against each value
- Bear case
- $45.34
- Price 74% above
- No growth
- …
- —
- Base case
- $76.67
- Price 3% above
What does Altria Group do?
Altria manufactures and distributes cigarettes, cigars, smokeless tobacco, and e-vapor products to adult consumers in the United States.
It brought in $23.5B of sales in the 12 months to Sep 2026.
- Industry
- Consumer staples
- Based in
- Richmond, Virginia
- Trades on
- NYSE as MO
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 35¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 37¢ of every dollar.
- Making what it sells37¢
- Everything else it takes to operate16¢
- Interest and other costs2¢
- Tax11¢
- Left as profit35¢
Who pays Altria Group, and for what?
Altria sells cigarettes, cigars, moist smokeless tobacco, oral nicotine pouches and e-vapor products, mainly in the United States. It makes money by manufacturing or sourcing these products and selling them through wholesalers, distributors and large retailers.
Its direct customers are mainly wholesalers, distributors, chain stores and other large retailers, while the products are used by U.S. adult nicotine consumers age 21 and older.
Smokeable products
88%Cigarettes, led by Marlboro, and machine-made large cigars, led by Black & Mild.
Oral tobacco products
12%Moist smokeless tobacco, including Copenhagen, Skoal and Red Seal, plus on! oral nicotine pouches.
Copenhagen moist smokeless tobacco tinsImage: Altria Group E-vapor products
NJOY e-vapor products. The segment reported negative net revenue in 2025 because of special items, so a meaningful revenue share is not disclosed.
All other
0%Horizon, Helix International and other activities, including research and development for new product platforms and technologies.
Ploom heated tobacco deviceImage: Altria Group
Where its work physically happens, beyond headquarters:
- Philip Morris USA Manufacturing Center — Richmond, United States. This facility makes cigarettes and also houses production of cigars and oral nicotine pouches, tying it to Altria’s largest revenue segment and its smoke-free portfolio.
- USSTC Hopkinsville campus — Hopkinsville, United States. This significant oral-tobacco processing site is slated to absorb Nashville’s finishing and packaging work, making the expansion central to planned manufacturing savings.
- USSTC Nashville plant — Nashville, United States. The plant finishes and packages Copenhagen, Skoal, Red Seal and Husky products, with production scheduled to wind down through early 2028.
- Center for Research & Technology — Richmond, United States. The center conducts much of Altria’s research supporting smoke-free product development and regulatory applications.
How is the business doing?
Sales shrank from $26.2B in 2020 to $23.3B in 2025, about 2% a year.
Running the business leaves about 47¢ of each sales dollar as operating profit, up from 42¢ in 2020.
After paying for its upkeep and new investment, it had $9.1B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Altria says it exists to improve everyday moments for adult nicotine consumers while responsibly developing smoke-free and other products.
“Elevating the Everyday – one moment at a time”
What management says it is working on now:
Advance the smoke-free portfolio
Management is expanding on! PLUS, developing additional pouch varieties and strengths, and building a portfolio of FDA-authorized smoke-free products.
Altria Reports 2026 Second-Quarter and First-Half ResultsStrengthen traditional tobacco
PM USA is using a total-portfolio approach across premium and discount cigarettes, including Marlboro Cowboy Cut and Basic, to support profitability as cigarette volumes decline.
Altria Reports 2026 Second-Quarter and First-Half ResultsModernize operations
The Optimize & Accelerate initiative centralizes work, outsources selected activities and standardizes or automates processes to improve speed and efficiency.
Altria 2025 Form 10-KBuild longer-term growth options
Altria plans to compete in international innovative oral tobacco markets, develop pathways into heated tobacco and e-vapor, and enter non-nicotine categories.
Altria 2025 Form 10-KImprove regulatory enforcement
The company is engaging with the FDA and other agencies to encourage action against illicit flavored disposable e-vapor products and support a regulated smoke-free market.
Altria 2025 Form 10-K
- Adjusted diluted EPS growth, By 2028
- Mid-single-digit compound annual growth from a $4.87 base
- 2028 Enterprise Goals - Altria
- Total adjusted operating companies income margin, Each year through 2028
- At least 60%
- 2028 Enterprise Goals - Altria
- Non-nicotine products, By 2028
- At least five products with broad commercial distribution
- 2028 Enterprise Goals - Altria
- 2026 adjusted diluted EPS, Full year 2026
- $5.61 to $5.72
- Altria Reports 2026 Second-Quarter and First-Half Results
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 1% more than a year earlier. The year before, quarters averaged -0%.
Its operating margin is about where it was a year ago, 54¢ per sales dollar.
Since Oct 2026 the share price has risen 7%, from $73.83 to $78.90.
Recently
July 30, 2026
Marlboro total cigarette retail share, Q2 changed to 39.5%
Altria Q2 2026 earnings releaseJuly 30, 2026
Revenues net of excise taxes, Q2 quarter changed to $5.4B
Altria Q2 2026 earnings releaseDecember 31, 2025
Domestic Cigarette Shipment Volume (Annual) changed to 61.8 number
Altria Group Full-Year 2025 Earnings Release
Coming up
October 29, 2026
Third-quarter and nine-month results
Altria is scheduled to report third-quarter and nine-month 2026 results and discuss them with investors.
Altria to Host Webcast of 2026 Third-Quarter and Nine-Months ResultsThird quarter 2026
on! PLUS national expansion
Altria said it planned a third-quarter national expansion of 12-milligram on! PLUS shipments after resuming shipments in selected states.
Altria Reports 2026 Second-Quarter and First-Half ResultsBeginning in the fourth quarter of 2026
New on! PLUS flavors and strengths
Helix plans to add flavors including Blueberry Mint and Mango Pineapple across 6-, 9- and 12-milligram strengths.
Altria Reports 2026 Second-Quarter and First-Half ResultsImplementation timing to be announced
USSTC manufacturing relocation
U.S. Smokeless Tobacco Company announced plans to modernize its manufacturing footprint through a facility relocation, which could affect future capacity and costs.
U.S. Smokeless Tobacco Co. Expansion Fuels Growth
Our own estimate moved too: the base case went from $49.22 to $76.67 a share between our last two valuations. The biggest reason: on! Nicotine Pouch Shipment Volume (Annual) moved from an unreported prior value to 177.8 number, as reported in Altria Group Full-Year 2025 Earnings Release.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Declining cigarette and smokeless volumes
Consumers are moving away from cigarettes and moist smokeless tobacco toward other nicotine products. Lower volumes could reduce revenue and make it harder to offset declines with price increases.
From the company's own filingsWould hit how fast sales growAltria 2025 Form 10-K
Regulatory approvals and enforcement
The FDA may delay, deny or withdraw authorization for new products. Weak enforcement against unauthorized e-vapor products could also make it harder for Altria's legal products to compete.
From the company's own filingsWould hit how fast sales growAltria 2025 Form 10-K
Competition in smoke-free products
Altria faces competition from innovative nicotine products, including oral pouches and e-vapor products. Failure to win consumers in these categories could reduce market share and future growth.
From the company's own filingsWould hit how fast sales growAltria 2025 Form 10-K
NJOY legal and execution problems
Import and sales bans on NJOY ACE and related patent disputes have already reduced the value of the e-vapor business. Further unfavorable outcomes could cause more losses or impairments.
From the company's own filingsWould hit how fast sales growAltria 2025 Form 10-K
Pressure on premium brands
Inflation and weaker household finances may lead consumers to buy discount brands or reduce consumption. This could limit Altria's ability to raise prices enough to protect profit margins.
From the company's own filingsWould hit how much of each sale it keepsAltria 2025 Form 10-K
Supply and manufacturing disruptions
Weather, tariffs, geopolitical events, labor problems or failures at key facilities and suppliers could raise costs or interrupt production and distribution.
From the company's own filingsWould hit how much of each sale it keepsAltria 2025 Form 10-K
Full-year consolidated revenue contracted by 3.08% in 2025 and 1.90% in 2024 as overall cigarette category volumes dropped by double digits.
From our researchWould hit how fast sales growAltria Group Form 10-K Filings
Operating margins dropped to 28.24% in Q4 2025 due to trademark adjustments and annual Master Settlement Agreement true-ups.
From our researchWould hit how much of each sale it keepsAltria Q4 2025 Earnings Release
Is it a good business?
From 2014 to 2025 it earned between 22% and 42% on the capital invested in it, a median of 35%. Its cost of capital in the latest valuation is 7.0%; returns were above it in every one of the 10 years.
From 2014 to 2020 it earned between 66% and 182% on its shareholders' equity, a median of 157%.
Over 10 years its operating margin ranged from 31¢ to 47¢ per sales dollar, a median of 42¢. Gross margin ran from 41¢ to 62¢.
Cost of capital 7.0%
The number of shares has held roughly steady over the past year.
It owes $21.4B more than it holds in cash, about 1.9 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $78.90. Our put its value between $45.34 and $104.80, with $76.67 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $45.34
Under this cautious outlook, steep declines in traditional cigarette smoking outpace price increases and squeeze company profits, keeping sales on a persistent downward path.
Base case, $76.67
Under this baseline scenario, regular price increases and steady growth in oral nicotine pouches largely balance out ongoing declines in traditional cigarette sales, stabilizing profits at current healthy levels.
Bull case, $104.80
Under this favorable scenario, robust demand for smoke-free nicotine pouches and tighter enforcement against illegal vapes return total sales to modest growth while lifting profits to record highs.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price and our value are close.Price above value: 3%
At today's $78.90, the price makes sense if sales shrink about 0.3% a year. We assume they shrink 0.8%. Over the last 5 years, sales shrank 2.0% a year.
Or, if sales shrink 0.8% as we assume, the price works with a profit margin of 52.8% (we assume 51.5%).
Keep in mind: a gap this small is normal. A small change in almost any assumption would close it.
Do you think sales will shrink about 0.3% a year?
Try your own numbersWe're moderately sure of this range: it scores 66 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $76.67 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average-0.8%
- Operating margin51.5%
- Long-term growth rate1.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$76.67 -2.8%

